Business Context and Reporting Period
This Form 8-K Current Report was filed by Emergent BioSolutions Inc. on October 25, 2018. The filing addresses a specific legal event under Item 8.01 (Other Events) involving the company's Adapt subsidiaries and Opiant Pharmaceuticals, Inc. regarding the intellectual property protection of NARCAN Nasal Spray.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal proceeding and does not contain financial statement data.
Material Changes and Legal Proceedings
- Event: On September 14, 2018, Perrigo UK FINCO Limited Partnership notified Adapt and Opiant of an Abbreviated New Drug Application (ANDA) filed with the FDA for a generic version of NARCAN Nasal Spray.
- Patents Involved: The ANDA challenges U.S. Patent Nos. 9,211,253, 9,468,747, 9,561,177, 9,629,965, and 9,775,838.
- Legal Action: On October 25, 2018, Emergent's subsidiaries and Opiant filed a patent infringement complaint against Perrigo in the U.S. District Court for the District of New Jersey.
- Regulatory Impact: The lawsuit triggers a 30-month stay on FDA approval of Perrigo's ANDA under the Hatch-Waxman Act, expected to last until March 2021 unless an earlier unfavorable judgment is issued.
Outlook, Risks, and Management Commentary
Management states that Emergent continues to vigorously enforce its intellectual property portfolio related to NARCAN Nasal Spray. The primary risk identified is the potential for generic market entry if the court rules unfavorably before the patent expiration dates. The company seeks an order delaying FDA approval until patent expiration, injunctive relief, and monetary damages.
Investor Verification Checklist
- Verify the status of the patent infringement lawsuit in the U.S. District Court for the District of New Jersey.
- Monitor the expiration dates of the five Patents-In-Suit to understand the maximum potential exclusivity period.
- Assess the potential financial impact of a generic NARCAN Nasal Spray entering the market prior to March 2021.
- Review subsequent filings for any updates on the 30-month stay or court rulings.